ATAI Life Sciences N.V. (ATAI) financial statements (2022 and earlier)

Company profile

Business Address 180 VARICK STREET
NEW YORK, NY 10014
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments362,266
Cash and cash equivalents362,266
Receivables913
Prepaid expense7,713
Other current assets756
Other undisclosed current assets3,434
Total current assets:375,082
Noncurrent Assets
Property, plant and equipment149
Long-term investments and receivables31,594
Long-term investments27,759
Due from related parties3,835
Other noncurrent assets7,341
Total noncurrent assets:39,084
TOTAL ASSETS:414,166
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20,833
Accounts payable6,004
Accrued liabilities14,829
Business combination, contingent consideration, liability51
Other liabilities51
Total current liabilities:20,935
Noncurrent Liabilities
Long-term debt and lease obligation743
Long-term debt, excluding current maturities743
Liabilities, other than long-term debt6,529
Other liabilities4,097
Business combination, contingent consideration, liability2,432
Total noncurrent liabilities:7,272
Total liabilities:28,207
Stockholders' equity
Stockholders' equity attributable to parent376,908
Common stock18,002
Additional paid in capital725,045
Accumulated other comprehensive loss(8,336)
Accumulated deficit(357,803)
Stockholders' equity attributable to noncontrolling interest9,051
Total stockholders' equity:385,959
TOTAL LIABILITIES AND EQUITY:414,166

Income statement (P&L) ($ in thousands)

12/31/2021
Revenues20,376
Gross profit:20,376
Operating expenses(156,181)
Operating loss:(135,805)
Nonoperating expense(796)
Investment income, nonoperating205
Foreign currency transaction gain, before tax8,481
Other nonoperating expense(293)
Loss from continuing operations before equity method investments, income taxes:(136,601)
Loss from equity method investments(58,555)
Other undisclosed income from continuing operations before income taxes58,555
Loss from continuing operations before income taxes:(136,601)
Income tax benefit3,989
Loss before gain (loss) on sale of properties:(132,612)
Other undisclosed net loss(41,632)
Net loss:(174,244)
Net income attributable to noncontrolling interest6,436
Net loss available to common stockholders, diluted:(167,808)

Comprehensive Income ($ in thousands)

12/31/2021
Net loss:(174,244)
Other undisclosed comprehensive loss(14,155)
Comprehensive loss:(188,399)
Comprehensive income, net of tax, attributable to noncontrolling interest6,460
Comprehensive loss, net of tax, attributable to parent:(181,939)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: